Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JCOG1701: Randomized phase III study comparing cessation or continuation of PD-1 Pathway Blockade for patients with advanced non-small-cell lung cancer

Next Previous
Search
Trial Profile

JCOG1701: Randomized phase III study comparing cessation or continuation of PD-1 Pathway Blockade for patients with advanced non-small-cell lung cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Bevacizumab; Pemetrexed
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms SAVE study

    • Most Recent Events

    • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2024 New trial record
    • 23 May 2024 According to a Natera media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 -June 4, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top